Artesunate (WR-256283)

InformationArtesunate (WR-256283) is a part of the artemisinin group of agents with an IC50 of < 5 μM for small cell lung carcinoma cell line H69. It is a potential inhibitor ofSTAT-3and exhibits selective cytotoxicity of cancer cells over normal cells in vitro; A pIn vitroART could alter the biomechanical properties of the glioma cells to inhibit cell proliferation, migration and invasion .The ART significantly suppresses the cell proliferation, induces the apoptosis and promoted cell cycle arrest at G0/G1 phase in SKM-1 cells. The mechanisms of ART anti-MDS is associated with the increase of intracellular calciumion concentration and ROS levels. In addition, the pro-apoptotic activity of ART may be involved in the regulation of BCL-2 /BAX ratio and the expressions of P-bad and survivin. ART treatment demethylates CDH1, which, in turn recovers the E-cadherin activation in SKM-1 cells.In vivoArtesunate is a medication used to treat malaria. Artesunate can induce radiosensitivity of HeLa cells in vivo using Xenograft model of nude mice. Artesunate had a relatively high immunosuppressive activity with low toxicity, and could inhibit T lymphocyte proliferation induced by mitogen and alloantigen.Cell Datacell lines：Concentrations：0, 12.5, 25, 50 µg/mLIncubation Time：0, 24, 48, and 72 hPowder Purity:≥97%.

Specifications and Purity: 10mM in DMSO

Molecular Formula: C19H28O8

Molecular Weight: 384.42